

# Vladimir Wsól

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8974346/publications.pdf>

Version: 2024-02-01

94  
papers

1,932  
citations

279487

23  
h-index

301761

39  
g-index

98  
all docs

98  
docs citations

98  
times ranked

2255  
citing authors

#	ARTICLE	IF	CITATIONS
1	PURIFICATION AND CHARACTERIZATION OF AKR1B10 FROM HUMAN LIVER: ROLE IN CARBONYL REDUCTION OF XENOBIOTICS. <i>Drug Metabolism and Disposition</i> , 2006, 34, 464-470.	1.7	106
2	Chiral Inversion of Drugs: Coincidence or Principle?. <i>Current Drug Metabolism</i> , 2004, 5, 517-533.	0.7	90
3	Comparison of in vitro activities of biotransformation enzymes in pig, cattle, goat and sheep. <i>Research in Veterinary Science</i> , 2004, 76, 43-51.	0.9	89
4	Salicylanilide derivatives block <i>Mycobacterium tuberculosis</i> through inhibition of isocitrate lyase and methionine aminopeptidase. <i>Tuberculosis</i> , 2012, 92, 434-439.	0.8	73
5	3-Phenyl-5-acyloxymethyl-2H,5H-furan-2-ones: Synthesis and Biological Activity of a Novel Group of Potential Antifungal Drugs. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 2701-2706.	2.9	71
6	Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3. <i>Toxicology Letters</i> , 2008, 181, 1-6.	0.4	69
7	Human Carbonyl Reductases. <i>Current Drug Metabolism</i> , 2010, 11, 639-658.	0.7	64
8	Carbonyl reduction pathways in drug metabolism. <i>Drug Metabolism Reviews</i> , 2014, 46, 96-123.	1.5	64
9	Anthracycline resistance mediated by reductive metabolism in cancer cells: The role of aldo-keto reductase 1C3. <i>Toxicology and Applied Pharmacology</i> , 2014, 278, 238-248.	1.3	59
10	AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids. <i>Chemico-Biological Interactions</i> , 2009, 178, 138-144.	1.7	56
11	Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29. <i>Chemico-Biological Interactions</i> , 2011, 191, 239-249.	1.7	48
12	Structural Basis for Substrate Specificity in Human Monomeric Carbonyl Reductases. <i>PLoS ONE</i> , 2009, 4, e7113.	1.1	47
13	Deeper Insight into the Reducing Biotransformation of Bupropion in the Human Liver. <i>Drug Metabolism and Pharmacokinetics</i> , 2014, 29, 177-184.	1.1	38
14	Aldo-keto reductases (AKR) from the AKR1C subfamily catalyze the carbonyl reduction of the novel anticancer drug oracin in man. <i>Toxicology</i> , 2007, 238, 111-118.	2.0	33
15	Human microsomal carbonyl reducing enzymes in the metabolism of xenobiotics: well-known and promising members of the SDR superfamily. <i>Drug Metabolism Reviews</i> , 2012, 44, 173-191.	1.5	33
16	Variations in the chemical profile and biological activities of licorice ( <i>Glycyrrhiza glabra</i> L.), as influenced by harvest times. <i>Acta Physiologiae Plantarum</i> , 2013, 35, 1337-1349.	1.0	33
17	Role of carbonyl reducing enzymes in the phase I biotransformation of the non-steroidal anti-inflammatory drug nabumetone in vitro. <i>Xenobiotica</i> , 2013, 43, 346-354.	0.5	33
18	Flavones Inhibit the Activity of AKR1B10, a Promising Therapeutic Target for Cancer Treatment. <i>Journal of Natural Products</i> , 2015, 78, 2666-2674.	1.5	31

#	ARTICLE	IF	CITATIONS
19	High-performance liquid chromatographic assay for the separation and characterization of metabolites of the potential cytostatic drug oracine. <i>Biomedical Applications</i> , 1996, 681, 169-175.	1.7	29
20	Effect of ivermectin on activities of cytochrome P450 isoenzymes in mouflon ( <i>Ovis musimon</i> ) and fallow deer ( <i>Dama dama</i> ). <i>Chemico-Biological Interactions</i> , 2001, 137, 155-167.	1.7	29
21	Anthracyclines and their metabolism in human liver microsomes and the participation of the new microsomal carbonyl reductase. <i>Chemico-Biological Interactions</i> , 2011, 191, 66-74.	1.7	29
22	Isoquinoline alkaloids as a novel type of AKR1C3 inhibitors. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2014, 143, 250-258.	1.2	27
23	Metabolite profile of sibutramine in human urine: a liquid chromatography-electrospray ionization mass spectrometric study. <i>Journal of Mass Spectrometry</i> , 2006, 41, 1171-1178.	0.7	24
24	Central composite design as a powerful optimisation technique for enantioresolution of the rac-11-dihydrooracinâ€”the principal metabolite of the potential cytostatic drug oracin. <i>Journal of Proteomics</i> , 2002, 54, 377-390.	2.4	23
25	Stereochemical aspects of carbonyl reduction of the original anticancer drug oracin by mouse liver microsomes and purified 11Î²-hydroxysteroid dehydrogenase type 1. <i>Chemico-Biological Interactions</i> , 2003, 143-144, 459-468.	1.7	23
26	Biochemical properties of human dehydrogenase/reductase (SDR family) member 7. <i>Chemico-Biological Interactions</i> , 2014, 207, 52-57.	1.7	23
27	Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile. <i>Archives of Toxicology</i> , 2018, 92, 2845-2857.	1.9	23
28	Pharmacokinetic interactions of breast cancer chemotherapeutics with human doxorubicin reductases. <i>Biochemical Pharmacology</i> , 2015, 96, 168-178.	2.0	22
29	Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment. <i>Biochemical Pharmacology</i> , 2018, 156, 22-31.	2.0	22
30	Carbonyl reduction of the potential cytostatic drugs benfluron and 3,9-dimethoxybenfluron in human in vitro. <i>Biochemical Pharmacology</i> , 2002, 64, 297-305.	2.0	21
31	Stereospecificity of flobufen metabolism in guinea pigs in vitro and in vivo: Phase I of biotransformation. <i>Chirality</i> , 2004, 16, 1-9.	1.3	21
32	Studies on reduction of S-nitrosoglutathione by human carbonyl reductases 1 and 3. <i>Chemico-Biological Interactions</i> , 2011, 191, 95-103.	1.7	21
33	Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment. <i>Current Neuropharmacology</i> , 2017, 15, 637-653.	1.4	21
34	The novel anticancer drug oracin: different stereospecificity and cooperativity for carbonyl reduction by purified human liver 11Î²-hydroxysteroid dehydrogenase type 1. <i>Toxicology</i> , 2004, 197, 253-261.	2.0	20
35	Synthesis and inÂvitro antimycobacterial and isocitrate lyase inhibition properties of novel 2-methoxy-2-â€”hydroxybenzanilides, their thioxo analogues and benzoxazoles. <i>European Journal of Medicinal Chemistry</i> , 2012, 56, 108-119.	2.6	20
36	Liver microsomal biotransformation of albendazole in deer, cattle, sheep and pig and some related wild breeds. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2005, 28, 377-384.	0.6	18

#	ARTICLE	IF	CITATIONS
37	Carbonyl reduction of warfarin: Identification and characterization of human warfarin reductases. <i>Biochemical Pharmacology</i> , 2016, 109, 83-90.	2.0	18
38	Inhibition of human anthracycline reductases by emodin – A possible remedy for anthracycline resistance. <i>Toxicology and Applied Pharmacology</i> , 2016, 293, 21-29.	1.3	18
39	11 $\beta$ -Hydroxysteroid dehydrogenase type 1: Purification from human liver and characterization as carbonyl reductase of xenobiotics. <i>Molecular and Cellular Endocrinology</i> , 2006, 248, 34-37.	1.6	17
40	The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man. <i>Chemico-Biological Interactions</i> , 2014, 220, 241-247.	1.7	17
41	Human DHRS7, promising enzyme in metabolism of steroids and retinoids?. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2016, 155, 112-119.	1.2	17
42	High-performance liquid chromatography study of stereospecific microsomal enzymes catalysing the reduction of a potential cytostatic drug, oracin. <i>Journal of Chromatography A</i> , 1998, 797, 197-201.	1.8	15
43	Reduction of the Potential Anticancer Drug Oracin in the Rat Liver In-vitro. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 52, 495-500.	1.2	15
44	Liquid chromatography–tandem mass spectrometry in chiral study of amlodipine biotransformation in rat hepatocytes. <i>Analytica Chimica Acta</i> , 2006, 573-574, 273-283.	2.6	14
45	Sex differences in stereospecificity of oracin reductases in rat in vitro and in vivo. , 1999, 11, 505-509.		13
46	Albendazole repeated administration induces cytochromes P4501A and accelerates albendazole deactivation in mouflon ( <i>Ovis musimon</i> ). <i>Research in Veterinary Science</i> , 2005, 78, 255-263.	0.9	13
47	Molecular and biochemical characterisation of human short-chain dehydrogenase/reductase member 3 (DHRS3). <i>Chemico-Biological Interactions</i> , 2015, 234, 178-187.	1.7	13
48	Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors. <i>Cancers</i> , 2020, 12, 1596.	1.7	13
49	Stereospecificity and stereoselectivity of flobufen metabolic profile in male rats in vitro and in vivo: Phase I of biotransformation. <i>Chirality</i> , 2001, 13, 754-759.	1.3	12
50	Stereospecific biotransformation of albendazole in mouflon and rat-isolated hepatocytes. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2003, 26, 297-302.	0.6	12
51	Partial purification and characterization of a new human membrane-bound carbonyl reductase playing a role in the deactivation of the anticancer drug oracin. <i>Toxicology</i> , 2009, 264, 52-60.	2.0	12
52	The stereoselective biotransformation of the anti-obesity drug sibutramine in rat liver microsomes and in primary cultures of rat hepatocytes. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 57, 405-410.	1.2	12
53	Inhibition of Nitric Oxide Synthase Prevents Muscarinic and Purinergic Functional Changes and Development of Cyclophosphamide-Induced Cystitis in the Rat. <i>BioMed Research International</i> , 2014, 2014, 1-12.	0.9	12
54	Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3. <i>Chemico-Biological Interactions</i> , 2019, 302, 101-107.	1.7	11

#	ARTICLE	IF	CITATIONS
55	Bruton's Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3. <i>Cancers</i> , 2020, 12, 3731.	1.7	11
56	Metabolic pathways of flobufen – a new antirheumatic and antiarthritic drug. Interspecies comparison. <i>Experimental and Toxicologic Pathology</i> , 1999, 51, 352-356.	2.1	10
57	Effect of substituents on microsomal reduction of benzo(c)fluorene N-oxides. <i>Chemico-Biological Interactions</i> , 2000, 126, 185-200.	1.7	10
58	Expression of human carbonyl reductase 3 (CBR3; SDR21C2) is inducible by pro-inflammatory stimuli. <i>Biochemical and Biophysical Research Communications</i> , 2012, 420, 368-373.	1.0	9
59	S-Nitrosoglutathione covalently modifies cysteine residues of human carbonyl reductase 1 and affects its activity. <i>Chemico-Biological Interactions</i> , 2013, 202, 136-145.	1.7	9
60	Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: Interaction with carbonyl-reducing enzymes and ABC transporters. <i>Biochemical Pharmacology</i> , 2019, 163, 290-298.	2.0	9
61	Separation of the stereoisomers of the main metabolite of a non-steroidal anti-inflammatory drug, flobufen, by chiral high-performance liquid chromatography. <i>Biomedical Applications</i> , 1997, 689, 205-214.	1.7	8
62	Stereoselective pharmacokinetics of flobufen in rats. , 1999, 11, 781-786.		8
63	A comparison between stereospecificity of oracin reduction and stereoselectivity of oxidation of 11-dihydrooracin enantiomers in vitro in rat and guinea pig. , 1999, 11, 510-515.		8
64	Purification and reconstitution of human membrane-bound DHRS7 (SDR34C1) from Sf9 cells. <i>Protein Expression and Purification</i> , 2014, 95, 44-49.	0.6	8
65	Chiral aspects of metabolism of antiinflammatory drug flobufen in human hepatocytes. <i>Chirality</i> , 2003, 15, 433-440.	1.3	7
66	Synthesis and Biological Activity of Quaternary Ammonium Salt-type Agents Containing Cholesterol and Terpenes. <i>Archiv Der Pharmazie</i> , 2014, 347, 381-386.	2.1	7
67	In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. <i>Chemico-Biological Interactions</i> , 2016, 258, 153-158.	1.7	7
68	Initial characterization of human DHRS1 (SDR19C1), a member of the short-chain dehydrogenase/reductase superfamily. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2019, 185, 80-89.	1.2	7
69	Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C3. <i>Cancers</i> , 2020, 12, 3127.	1.7	7
70	Stereoselective pharmacokinetics and metabolism of flobufen in guinea pigs. <i>Chirality</i> , 2003, 15, 724-729.	1.3	6
71	Use of chiral liquid chromatography for the evaluation of stereospecificity in the carbonyl reduction of potential benzo[c]fluorene antineoplastics benfluron and dimefluron in various species. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2005, 37, 1049-1057.	1.4	6
72	Enzyme Stereospecificity as a Powerful Tool in Searching for New Enzymes. <i>Current Drug Metabolism</i> , 2010, 11, 547-559.	0.7	6

#	ARTICLE	IF	CITATIONS
73	Human dehydrogenase/reductase (SDR family) member 8 (DHRS8): a description and evaluation of its biochemical properties. <i>Molecular and Cellular Biochemistry</i> , 2016, 411, 35-42.	1.4	6
74	Biotransformation of flobufen enantiomers in ruminant hepatocytes and subcellular fractions. <i>Chirality</i> , 2001, 13, 760-764.	1.3	5
75	Characterization of enzymes responsible for biotransformation of the new antileukotrienic drug quinlukast in rat liver microsomes and in primary cultures of rat hepatocytes. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 56, 205-212.	1.2	5
76	<i>In vitro</i> functional interactions of acetylcholine esterase inhibitors and muscarinic receptor antagonists in the urinary bladder of the rat. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2014, 41, 139-146.	0.9	5
77	Design, Synthesis, and Biological Evaluation of Isothiosemicarbazones with Antimycobacterial Activity. <i>Archiv Der Pharmazie</i> , 2017, 350, 1700020.	2.1	5
78	AKR1C3 Inhibitory Potency of Naturally-occurring Amaryllidaceae Alkaloids of Different Structural Types. <i>Natural Product Communications</i> , 2017, 12, 1934578X1701200.	0.2	5
79	Selective inhibition of aldo-keto reductase 1C3: a novel mechanism involved in midostaurin and daunorubicin synergism. <i>Archives of Toxicology</i> , 2021, 95, 67-78.	1.9	5
80	A Simple Identification of Novel Carbonyl Reducing Enzymes in the Metabolism of the Tobacco Specific Carcinogen NNK. <i>Drug Metabolism Letters</i> , 2013, 6, 174-181.	0.5	5
81	The stereospecificity of flobufen metabolism in isolated guinea pig hepatocytes. <i>BMC Pharmacology</i> , 2003, 3, 5.	0.4	4
82	Hydantoins and Thiohydantoins Derived from 1,2,3,4-Tetrahydroisoquinoline-3-carboxylic Acid. <i>Heterocycles</i> , 2006, 68, 2527.	0.4	4
83	Coordination Compounds Based on 1,2,3,4-Tetrahydro-isoquinoline-3-carboxylic Acid. <i>Molecules</i> , 2007, 12, 1064-1079.	1.7	4
84	Interactions of antileukemic drugs with daunorubicin reductases: could reductases affect the clinical efficacy of daunorubicin chemoregimens?. <i>Archives of Toxicology</i> , 2020, 94, 3059-3068.	1.9	4
85	The Phase I Biotransformation of the Potential Antileukotrienic Drug Quinlukast in Rat Microsomes and Hepatocytes. <i>Collection of Czechoslovak Chemical Communications</i> , 2004, 69, 689-702.	1.0	4
86	Reduction of flobufen in pig hepatocytes: Effect of pig breed (domestic, wild) and castration. <i>Chirality</i> , 2003, 15, 213-219.	1.3	3
87	Liquid chromatographic-electrospray mass spectrometric determination (LC-ESI-MS) of phase II metabolites of flobufen in rat liver microsomes-Chiral discrimination. <i>Talanta</i> , 2008, 75, 494-502.	2.9	3
88	HPLC-radiometric determination of quinlukast in biological fluids. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2004, 35, 177-183.	1.4	2
89	Efficient isolation of carbonyl-reducing enzymes using affinity approach with anticancer drug oracin as a specific ligand. <i>Journal of Separation Science</i> , 2013, 36, 1176-1184.	1.3	2
90	Carbonyl-reducing enzymes as targets of a drug-immobilised affinity carrier. <i>Chemico-Biological Interactions</i> , 2015, 234, 169-177.	1.7	2

#	ARTICLE	IF	CITATIONS
91	Reductive metabolism of tiaprofenic acid by the human liver and recombinant carbonyl reducing enzymes. <i>Chemico-Biological Interactions</i> , 2017, 276, 121-126.	1.7	2
92	Inhibition of AKR1B10-mediated metabolism of daunorubicin as a novel off-target effect for the Bcr-Abl tyrosine kinase inhibitor dasatinib. <i>Biochemical Pharmacology</i> , 2021, 192, 114710.	2.0	2
93	Activity, stereospecificity, and stereoselectivity of microsomal enzymes in dependence on storage and freezing of rat liver samples. <i>Chirality</i> , 2000, 12, 649-653.	1.3	1
94	Stereospecific reduction of the original anticancer drug oracin in rat extrahepatic tissues. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 55, 1003-1011.	1.2	1